Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Prefilled autoinjector Clear all
Completed Phase 3 Interventional Results available

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

NCT01879319
View directory record Official record
Conditions
Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions
Evolocumab AMD, Evolocumab AI/pen
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
22
States / cities
Phoenix, Arizona • Encino, California • Thousand Oaks, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

NCT03432533
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

NCT00828204
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
single-use autoinjector with a prefilled liquid Avonex syringe, Avonex prefilled syringe via manual IM injection, BG9418 (interferon beta-1a)
Device · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Maitland, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe

NCT06114238
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab AI, Itepekimab PFS
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device

NCT01618955
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
VIBEX MTX
Device
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Injections of LY3074828 in Healthy Participants

NCT03886948
View directory record Official record
Conditions
Healthy
Interventions
LY3074828, Pre-filled syringe (PFS), Autoinjector (AI)
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 25, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional

Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation

NCT05917522
View directory record Official record
Conditions
Kidney Transplant
Interventions
Abatacept, Standard of Care at US Transplant Centers
Biological · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Galcanezumab in Healthy Participants.

NCT02836613
View directory record Official record
Conditions
Healthy
Interventions
Galcanezumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe

NCT02636907
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
BI 695501 Autoinjector, BI 695501 Prefilled syringe
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Upland, California • Venice, Florida • Cumberland, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

NCT00319501
View directory record Official record
Conditions
Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions
Placebo, Vanquix Auto-Injector (Diazepam Injection)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
86
States / cities
Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Results available

Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe

NCT01890473
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Huntsville, Alabama • Centennial, Colorado • Daytona Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 25, 2026, 8:14 PM EDT
Enrolling by invitation Phase 3 Interventional

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Selatogrel, Placebo
Combination Product
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years and older
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
81
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

NCT01901185
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis
Interventions
Etanercept / Autoinjector A
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

NCT02986139
View directory record Official record
Conditions
Arthritis, Rheumatoid; Arthritis, Psoriatic
Interventions
Commercial Formulation Etanercept, New Formulation Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • El Cajon, California • Lomita, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

NCT01984424
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe, Ezetimibe, Placebo to Evolocumab, Evolocumab
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961295
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Remternetug (LY3372993) in Healthy Participants

NCT07056309
View directory record Official record
Conditions
Healthy
Interventions
Remternetug (Test), Remternetug (Reference)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Effect of Evolocumab on Coronary Atherosclerosis

NCT03689946
View directory record Official record
Conditions
Cardiovascular Disease, Hyperlipidemia
Interventions
Evolocumab, 18F-NaF PET, CCTA, Omnipaque, Metoprolol, Nitroglycerin
Drug · Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 25, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

NCT05684692
View directory record Official record
Conditions
Schwannomatosis, Schwannomas, Pain, Chronic
Interventions
Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo, Erenumab-Aooe Matching Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects

NCT01894360
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 200 mg/mL
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

NCT01764633
View directory record Official record
Conditions
Dyslipidemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
27,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
326
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 275 more
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Sep 25, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants

NCT05069896
View directory record Official record
Conditions
Healthy
Interventions
Mirikizumab Prefilled Syringe, Mirikizumab Autoinjector
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 25, 2026, 8:14 PM EDT